EDMONTON, Alberta--(BUSINESS WIRE)--Oct. 24, 2005--ViRexx Medical Corp. (TSX:VIR), a company focused on immunotherapy treatments for cancer, chronic hepatitis B & C and embolotherapy treatments for tumors today announced that Dr. Lorne Tyrrell has been named the Company's Chief Executive Officer by the Board of Directors effective November 1, 2005. Dr. Tyrrell replaces Dr. Antoine Noujaim who is on an extended medical leave. Dr. Tyrrell is a world pioneer in virology, and in particular developing Lamivudine(R) the world's first antiviral oral treatment for Hepatitis B which is licensed in more than 100 countries.
